Two Main Cancer Biomarkers as Molecular Targets of Binase Antitumor Activity

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Cancer frequently involves dysregulated signaling pathways, notably the mitogen-activated protein kinase (MAPK) cascade, activated in over 85% of cancers.
• Genetic alterations in key components like EGFR (Epidermal Growth Factor Receptor) and RAS oncogenes drive MAPK pathway hyperactivation, crucial for cell fate.
• Despite their importance, effective targeted therapies against EGFR and RAS remain elusive.

Purpose of the Study:

• To investigate the potential of ribonuclease from Bacillus pumilus (binase) as an anticancer agent.
• To elucidate the mechanism by which binase affects MAPK signaling and its interaction with EGFR and RAS.
• To evaluate binase's potential to overcome therapeutic resistance in cancer treatment.

Main Methods:

• Direct interaction studies between binase, EGFR, and RAS proteins.
• Assessment of binase's effect on MAPK signaling pathway activity.
• Evaluation of binase's antitumor potential and its impact on drug resistance development.

Main Results:

• Binase directly interacts with both EGFR and RAS proteins, inhibiting MAPK signaling.
• This inhibition contributes to binase's observed antitumor effects, complementing its enzymatic activity.
• The multitargeting nature of binase demonstrates potential in preventing the emergence of drug resistance.

Conclusions:

• Binase exhibits significant potential as a novel anticancer therapeutic by simultaneously targeting key oncogenes EGFR and RAS.
• The direct inhibition of MAPK signaling by binase offers a new strategy to combat cancers driven by these alterations.
• Binase's multitargeting capability is crucial for overcoming drug resistance, a major challenge in current cancer treatments.